Avacta Group plc ( (GB:AVCT) ) has provided an update.
Avacta Therapeutics announced its participation in the 2025 AACR Annual Meeting, where it will present data on its innovative peptide drug conjugates (PDCs) developed using the pre|CISION® platform. These presentations will highlight the pharmacokinetics and clinical potential of AVA6000 and AVA6103, as well as insights into the fibroblast activation protein-alpha (FAPα) that underpins their targeted delivery mechanism. This announcement underscores Avacta’s commitment to advancing cancer treatment and its strategic positioning in the oncology sector.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage life sciences company focused on developing highly potent cancer therapies using its proprietary pre|CISION® platform. This platform targets tumor-specific proteases to deliver anticancer drugs directly to the tumor microenvironment, minimizing damage to healthy tissues and optimizing patient outcomes.
YTD Price Performance: -24.50%
Average Trading Volume: 1,709,046
Technical Sentiment Signal: Buy
Current Market Cap: £138.9M
Find detailed analytics on AVCT stock on TipRanks’ Stock Analysis page.